MacroGenics announced that it has entered into an agreement to sell its royalty interest on future global net sales of TZIELD to a wholly-owned subsidiary of DRI Healthcare Trust for up to $200M. MacroGenics retains its other economic interests related to TZIELD, including future potential regulatory and commercial milestones. Under the terms of the agreement with DRI, MacroGenics will receive a $100M upfront payment for the sale of its single-digit royalty on global net sales of TZIELD. MacroGenics will have the right to receive a 50% share of the royalty on global net sales above a certain annual threshold. In addition, the company is eligible to receive up to $50M from DRI upon the occurrence of pre-specified events tied to the advancement of TZIELD for the treatment of newly diagnosed type 1 diabetes. The company may also receive an additional $50M if TZIELD achieves a certain level of net sales.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MGNX:
- MacroGenics Announces Sale of TZIELD™ Royalty Interest for up to $200 Million
- MacroGenics Announces Date of Fourth Quarter 2022 Financial Results Conference Call
- MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics Announces Preliminary Clinical Results from Single Arm Study of Lorigerlimab in Patients with Metastatic Castration-Resistant Prostate Cancer to be Presented at ASCO Genitourinary Cancers Symposium
- MacroGenics to present clinical results from Lorigerlimab study at ASCO